BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15350628)

  • 1. p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours.
    Paluszkiewicz P; Berbeć H; Pawłowska-Wakowicz B; Cybulski M; Paszkowska A
    Cancer Detect Prev; 2004; 28(4):252-9. PubMed ID: 15350628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
    Zhang Hong
    Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor.
    Adrover E; Maestro ML; Sanz-Casla MT; del Barco V; Cerdán J; Fernández C; Balibrea JL
    Br J Cancer; 1999 Sep; 81(1):122-6. PubMed ID: 10487622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.
    Manne U; Gary BD; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
    Clin Cancer Res; 2001 Nov; 7(11):3495-503. PubMed ID: 11705868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of mucinous component in colorectal carcinoma.
    Papadopoulos VN; Michalopoulos A; Netta S; Basdanis G; Paramythiotis D; Zatagias A; Berovalis P; Harlaftis N
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s123-5. PubMed ID: 15655594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between DNA content and p53 deletion in colorectal cancer.
    Cianchi F; Balzi M; Becciolini A; Giachè V; Messerini L; Palomba A; Tisti E; Faraoni P; Chellini F; Pucciani F; Perigli G; Cortesini C
    Eur J Surg; 1999 Apr; 165(4):363-8. PubMed ID: 10365839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer.
    Lim SC; Lee TB; Choi CH; Ryu SY; Min YD; Kim KJ
    J Surg Oncol; 2008 Jan; 97(1):51-6. PubMed ID: 17929263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis.
    Aust DE; Muders M; Köhler A; Schmidt M; Diebold J; Müller C; Löhrs U; Waldman FM; Baretton GB
    Scand J Gastroenterol; 2004 Aug; 39(8):766-72. PubMed ID: 15513363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth dysregulation and p53 accumulation in human primary colorectal cancer.
    Watson DS; Brotherick I; Shenton BK; Wilson RG; Campbell FC
    Br J Cancer; 1999 Jun; 80(7):1062-8. PubMed ID: 10362117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis and p53 at the invading tumor edge: prognostic markers for colorectal cancer beyond stage.
    Georgiou L; Minopoulos G; Lirantzopoulos N; Fiska-Demetriou A; Maltezos E; Sivridis E
    J Surg Res; 2006 Mar; 131(1):118-23. PubMed ID: 16325858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma.
    Georgescu CV; Săftoiu A; Georgescu CC; Ciurea R; Ciurea T
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):133-9. PubMed ID: 17592558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
    Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
    Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
    Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.